Mathematical modeling has become a valuable tool that strives to complement conventional
biomedical research modalities in order to predict experimental outcome, generate new …

High drug attrition rates remain a critical issue in oncology drug development. A series of
steps during drug development must be addressed to better understand the …

Introduction: Modeling and simulation have become important means of answering
questions relevant to the development of a drug, making it possible to assess risks early and …

Purpose Physiologically based pharmacokinetic (PBPK) modeling, a mathematical
modeling approach which uses a pharmacokinetic model to mimick human physiology to …

Progress in an understanding of the genetic basis of cancer coupled to molecular
pharmacology of potential new anticancer drugs calls for new approaches that are able to …

The application of pharmacokinetic (PK) and pharmacodynamic (PD) modeling in drug
development has emerged during the past decades and it is has been suggested that the …

The use of pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug
research is a promising approach that provides better understanding of drug efficacy and …

In oncology trials, overall survival (OS) is considered the most reliable and preferred
endpoint to evaluate the benefit of drug treatment. Other relevant variables are also …

Purpose: GDC-0973 is a potent and selective mitogen-activated protein (MAP)/extracellular
signal–regulated kinase (ERK) kinase (MEK) inhibitor. Pharmacokinetic–pharmacodynamic …

Despite much investment and progress, oncology is still an area with significant unmet
medical needs, with new therapies and more effective use of current therapies needed. The …